NCAM1 and Alzheimer disease: When subsequently applied to plasma samples from a validation cohort, the assay also exhibited remarkable performance in distinguishing AD patients from HCs, achieving an AUROC of 0.968 for L1CAM(+)‐NEVs and 0.954 for NCAM(+)‐NEVs.